Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

• Status: Completed
• Trial end date: 2012-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough eyelashes) in children.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Children who have inadequate eyelashes or have lost their eyelashes as a result of chemotherapy treatment, who completed their chemotherapy (intensive treatment) at least 4 weeks before starting the study, are considered to be at low risk for relapse of their cancer, and are well enough to complete the study

• Children who have minimal to moderate inadequate eyelashes due to alopecia areata

• Adolescents between the ages of 15-17 years who have minimal to marked inadequate eyelashes

Exclusion Criteria:

• Any eye disease or abnormality, eye surgery, permanent eyeliner, eyelash implants.

• Semi-permanent eyelash tint, dye or eyelash extension application within 3 months

• Use of over the counter eyelash growth products within 6 months.

• Use of prescription eyelash growth products (eg, Latisse®)

• Any eye condition that would prevent required ophthalmology exams